The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205–212. PubMed PMID: 27573025. DOI:10.1111/jdv.13854.
   PubMed Web of Science ®Google Scholar
• Elder JT, Nair RP, Guo SW, et al. The genetics of psoriasis. Arch Dermatol. 1994 Feb;130(2):216–224. PubMed PMID: 8304761.
   PubMedGoogle Scholar
• Armstrong AW, Harskamp CT, Dhillon JS, et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014 Feb;170(2):304–314. PubMed PMID: 24117435. DOI:10.1111/bjd.12670
   PubMed Web of Science ®Google Scholar
• Poikolainen K, Reunala T, Karvonen J, et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ. 1990 Mar 24;300(6727):780–783. PubMed PMID: 1969757; PubMed Central PMCID: PMCPMC1662565.
   PubMedGoogle Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007 Feb 22;445(7130):866–873. PubMed PMID: 17314973. Doi:10.1038/nature05663.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Voyles SV, Armstrong EJ, et al. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci. 2011 Jul;63(1):1–9. PubMed PMID: 21600738. DOI:10.1016/j.jdermsci.2011.04.007
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006 May 11;441(7090):231–234. PubMed PMID: 16648837. DOI:10.1038/nature04754
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003 Feb 13;421(6924):744–748. PubMed PMID: 12610626. DOI:10.1038/nature01355
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015 Jul;21(7):719–729. PubMed PMID: 26121196. DOI:10.1038/nm.3895
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov;13(5):715–725. PubMed PMID: 11114383.
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002 Jan;46(1):1–23; quiz 23–6. PubMed PMID: 11756941.
   PubMed Web of Science ®Google Scholar
• Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008 Aug;159(Suppl 2):10–17. PubMed PMID: 18700910. DOI:10.1111/j.1365-2133.2008.08780.x.
   PubMedGoogle Scholar
• Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785–1796. PubMed PMID: 20445552. DOI:10.1038/jid.2010.103
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011 Apr;20(4):303–307. PubMed PMID: 21410760. DOI:10.1111/j.1600-0625.2011.01261.x
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010 Sep;163(3):586–592. PubMed PMID: 20633008; PubMed Central PMCID: PMCPMC2966545. DOI:10.1111/j.1365-2133.2010.09941.x
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007 Dec;143(12):1493–1499. PubMed PMID: 18086997. DOI:10.1001/archderm.143.12.1493
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. Jama. 2006 Oct 11;296(14):1735–1741. PubMed PMID: 17032986. DOI:10.1001/jama.296.14.1735
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:24–28. PubMed PMID: 22751586; PubMed Central PMCID: PMCPMC3670770. DOI:10.3899/jrheum.120237
   PubMedGoogle Scholar
• Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010 Apr;31(8):1000–1006. PubMed PMID: 20037179; PubMed Central PMCID: PMCPMC2894736. DOI:10.1093/eurheartj/ehp567
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006 Nov;55(5):829–835. PubMed PMID: 17052489. DOI:10.1016/j.jaad.2006.08.040
   PubMed Web of Science ®Google Scholar
• Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–132. PubMed PMID: 24790463; PubMed Central PMCID: PMCPMC4000177. DOI:10.2147/CCID.S44843
   PubMedGoogle Scholar
• Kivelevitch D, Schussler JM, Menter A. Coronary plaque characterization in psoriasis. Circulation. 2017 Jul 18;136(3):277–280. PubMed PMID: 28716831. Doi:10.1161/CIRCULATIONAHA.117.029126.
   PubMed Web of Science ®Google Scholar
• Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008 Sep;159(4):820–826. PubMed PMID: 18637894. DOI:10.1111/j.1365-2133.2008.08742.x
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008 Dec;144(12):1571–1575. PubMed PMID: 19075139. DOI:10.1001/archderm.144.12.1571
   PubMedGoogle Scholar
• Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S64–73. PubMed PMID: 18987272; PubMed Central PMCID: PMCPMC2585759. DOI:10.1210/jc.2008-1613.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016 Dec;12(12):1299–1308. PubMed PMID: 27322922. DOI:10.1080/1744666X.2016.1201423
   PubMed Web of Science ®Google Scholar
• Pietrzak A, Bartosinska J, Chodorowska G, et al. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol. 2013 Feb;52(2):153–162. PubMed PMID: 23347301. DOI:10.1111/j.1365-4632.2012.05584.x
   PubMed Web of Science ®Google Scholar
• Takeshita J, Mohler ER, Krishnamoorthy P, et al. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc. 2014;3(1):e000507. PubMed PMID: 24584739; PubMed Central PMCID: PMCPMC3959700. DOI:10.1161/JAHA.113.000507
   PubMed Web of Science ®Google Scholar
• Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012 Sep;224(1):218–221. PubMed PMID: 22858285; PubMed Central PMCID: PMCPMC3693845. DOI:10.1016/j.atherosclerosis.2012.06.068
   PubMed Web of Science ®Google Scholar
• Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017 Jul 06 PubMed PMID: 28681405. DOI:10.1111/jdv.14460.
   Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998 Nov;139(5):846–850. PubMed PMID: 9892952.
   PubMed Web of Science ®Google Scholar
• Devrimci-Ozguven H, Kundakci TN, Kumbasar H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000 Jul;14(4):267–271. PubMed PMID: 11204514.
   PubMed Web of Science ®Google Scholar
• Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010 Mar-Apr;23(2):174–180. PubMed PMID: 20415825. DOI:10.1111/j.1529-8019.2010.01312.x.
   PubMed Web of Science ®Google Scholar
• Hardy GE, Cotterill JA. A study of depression and obsessionality in dysmorphophobic and psoriatic patients. PubMed PMID: 7059736. Br J Psychiatry. 1982 Jan;140:19–22
   PubMed Web of Science ®Google Scholar
• Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002 Oct;47(4):512–518. PubMed PMID: 12271293.
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001 Mar;137(3):280–284. PubMed PMID: 11255325.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009 Feb;60(2):218–224. PubMed PMID: 19022533; PubMed Central PMCID: PMCPMC4762027. DOI:10.1016/j.jaad.2008.09.022.
   PubMed Web of Science ®Google Scholar
• Ferreira BI, Abreu JL, Reis JP, et al. Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol. 2016 Jun;9(6):36–43. PubMed PMID: 27386050; PubMed Central PMCID: PMCPMC4928455.
   PubMedGoogle Scholar
• Davami MH, Baharlou R, Ahmadi Vasmehjani A, et al. Elevated IL-17 and TGF-beta serum levels: a positive correlation between t-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Basic Clin Neurosci. 2016 Apr;7(2):137–142. PubMed PMID: 27303608; PubMed Central PMCID: PMCPMC4892318. DOI:10.15412/J.BCN.03070207
   PubMed Web of Science ®Google Scholar
• Perrott SB, Murray AH, Lowe J, et al. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000 Sep 15;70(5):567–571. PubMed PMID: 11111012.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392. PubMed PMID: 16343026.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology, Work G, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137–174. PubMed PMID: 21306785. Doi:10.1016/j.jaad.2010.11.055
   PubMed Web of Science ®Google Scholar
• Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010 Apr;24(Suppl 2):17–22. PubMed PMID: 20443996. DOI:10.1111/j.1468-3083.2009.03563.x
   PubMed Web of Science ®Google Scholar
• De Korte J, Mombers FM, Sprangers MA, et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002 Sep;138(9):1221–7;discussion 1227. PubMed PMID: 12224984.
   PubMedGoogle Scholar
• Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007 Dec;127(12):2726–2739. PubMed PMID: 17989733. DOI:10.1038/sj.jid.5701142
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995 May;75(3):240–243. PubMed PMID: 7653188.
   PubMed Web of Science ®Google Scholar
• McKenna SP, Cook SA, Whalley D, et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003 Aug;149(2):323–331. PubMed PMID: 12932239.
   PubMed Web of Science ®Google Scholar
• Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct;24(5):356–360. PubMed PMID: 23092173. DOI:10.3109/09546634.2012.742950
   PubMed Web of Science ®Google Scholar
• Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003 Aug 01;1:29. DOI:10.1186/1477-7525-1-29
   PubMedGoogle Scholar
• Zhang W, Bansback N, Boonen A, et al. Validity of the work productivity and activity impairment questionnaire–general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177. PubMed PMID: 20860837; PubMed Central PMCID: PMCPMC2991008. DOI:10.1186/ar3141
   PubMed Web of Science ®Google Scholar
• Evers AW, Duller P, Van De Kerkhof PC, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol. 2008 Jan;158(1):101–108. PubMed PMID: 17999699. DOI:10.1111/j.1365-2133.2007.08296.x
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Mutebi A, Milmont CE, et al. Measurement properties of the psoriasis symptom inventory electronic daily diary in patients with moderate to severe plaque psoriasis. Value Health. 2017 Sep;20(8):1174–1179. PubMed PMID: 28964451. DOI:10.1016/j.jval.2016.11.020
   PubMed Web of Science ®Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007 May;156(5):945–950. DOI:10.1111/j.1365-2133.2007.07817.x.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Gooderham M, Hartz S, et al. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J Med Econ. 2017 Jan;20(1):19–27. PubMed PMID: 27471948. DOI:10.1080/13696998.2016.1219359
   PubMed Web of Science ®Google Scholar
• Darjani A, Heidarzadeh A, Golchai J, et al. Quality of life in psoriatic patients: a study using the short form-36. Int J Prev Med. 2014 Sep;5(9):1146–1152. PubMed PMID: 25317298; PubMed Central PMCID: PMCPMC4192777.
   PubMedGoogle Scholar
• Martin ML, McCarrier KP, Chiou CF, et al. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013 Aug;24(4):255–260. PubMed PMID: 23249143. DOI:10.3109/09546634.2012.759639
   PubMed Web of Science ®Google Scholar
• Kivelevitch D, Michel P, Menter A. Quality of life instruments in psoriasis clinical trials. Br J Dermatol. 2017 Mar;176(3):563. PubMed PMID: 28300302. DOI:10.1111/bjd.15102.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007 Dec 24;204(13):3183–3194. PubMed PMID: 18039949; PubMed Central PMCID: PMCPMC2150965. DOI:10.1084/jem.20071094
   PubMed Web of Science ®Google Scholar
• Balato A, Schiattarella M, Di Caprio R, et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1016–1024. PubMed PMID: 24033358. DOI:10.1111/jdv.12240
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Poulin Y, et al. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2013 May;27(5):634–642. PubMed PMID: 22429586. DOI:10.1111/j.1468-3083.2012.04515.x
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan;58(1):106–115. PubMed PMID: 17936411. DOI:10.1016/j.jaad.2007.09.010
   PubMed Web of Science ®Google Scholar
• Mease PJ. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1–4. PubMed PMID: 12728284.
   PubMedGoogle Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. PubMed PMID: 10972371. DOI:10.1016/S0140-6736(00)02530-7
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003 Jan;48(1):68–75. PubMed PMID: 12522373. DOI:10.1067/mjd.2003.10
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 09;357(9271):1842–1847. PubMed PMID: 11410193.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. PubMed PMID: 14627786. DOI:10.1056/NEJMoa030409
   PubMed Web of Science ®Google Scholar
• Campanati A, Benfaremo D, Luchetti MM, et al. Certolizumab pegol for the treatment of psoriasis. Expert Opin Biol Ther. 2017 Mar;17(3):387–394. PubMed PMID: 28165828. DOI:10.1080/14712598.2017.1283401
   PubMed Web of Science ®Google Scholar
• Dermira. News release: Final Cimzia (certolizumab pegol) phase 3 trial meets primary efficacy endpoint in patients with moderate to severe chronic plaque psoriasis. 2017 Jan 18. [cited 2017 Nov 2]. Available from: https://eu.vocuspr.com/ViewAttachment.aspx?EID=hciRJLtApyzzYk8gYkD3EREuidEx9XV3VUEXldmjyE%3d
   Google Scholar
• Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012 Jul;167(1):180–190. PubMed PMID: 22413944. DOI:10.1111/j.1365-2133.2012.10941.x
   PubMed Web of Science ®Google Scholar
• Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18(1):25–31. PubMed PMID: 17365264. DOI:10.1080/09546630601121060
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct;55(4):598–606. PubMed PMID: 17010738. DOI:10.1016/j.jaad.2006.05.027
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341–350. PubMed PMID: 18058494. DOI:10.1080/09546630701646172
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May;152(5):954–960. PubMed PMID: 15888152. DOI:10.1111/j.1365-2133.2005.06510.x
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004 Oct;51(4):534–542. PubMed PMID: 15389187. DOI:10.1016/j.jaad.2004.02.021
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006 Jun;154(6):1161–1168. PubMed PMID: 16704649. DOI:10.1111/j.1365-2133.2006.07237.x
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005 Oct 15–21;366(9494):1367–1374. PubMed PMID: 16226614. DOI:10.1016/S0140-6736(05)67566-6
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005 Dec;153(6):1192–1199. PubMed PMID: 16307657. DOI:10.1111/j.1365-2133.2005.06948.x
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005 Jun;152(6):1304–1312. PubMed PMID: 15948997. DOI:10.1111/j.1365-2133.2005.06688.x
   PubMed Web of Science ®Google Scholar
• Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005 Nov;53(5):887–889. PubMed PMID: 16243150. DOI:10.1016/j.jaad.2005.06.053
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010 Jan;162(1):137–146. PubMed PMID: 19903183. DOI:10.1111/j.1365-2133.2009.09491.x
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665–1674. PubMed PMID: 18486739. DOI:10.1016/S0140-6736(08)60725-4
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep;63(3):457–465. PubMed PMID: 20462664. DOI:10.1016/j.jaad.2009.09.014
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675–1684. PubMed PMID: 18486740. DOI:10.1016/S0140-6736(08)60726-6
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181–1189. PubMed PMID: 22455412. DOI:10.1056/NEJMoa1109017
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016 Aug;175(2):273–286. PubMed PMID: 26914406. DOI:10.1111/bjd.14493
   PubMed Web of Science ®Google Scholar
• Strober B, Gordon K, Augustin M, et al. Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: results from AMAGINE-1 (Abstract). JAAD. 2016;74(5,Supple 1):AB256.
   Web of Science ®Google Scholar
• Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017 Mar 10 PubMed PMID: 28294430. DOI:10.1111/jdv.14211.
   Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015 Aug 08;386(9993):541–551. PubMed PMID: 26072109. DOI:10.1016/S0140-6736(15)60125-8
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–338. PubMed PMID: 25007392. DOI:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017 Jan;76(1):60–69 e9. PubMed PMID: 27663079. DOI:10.1016/j.jaad.2016.08.008
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017 Mar;76(3):405–417. PubMed PMID: 28057360. DOI:10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar;76(3):418–431. PubMed PMID: 28057361. DOI:10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, Phase 3 NAVIGATE trial. Br J Dermatol. 2017 Jun 21 PubMed PMID: 28635018. DOI:10.1111/bjd.15750.
   Google Scholar
• Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930–939. PubMed PMID: 26042589. DOI:10.1111/bjd.13932
   PubMed Web of Science ®Google Scholar
• Thaci D, Papp K, Reich K, et al. FRI0446 treatment with tildrakizumab, an anti-il-23p19 monoclonal antibody, improves health-related quality of life in patients with chronic plaque psoriasis (poster presentation). Ann Rheum Dis. 2016;75(Suppl 2):597.
   Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276–288. PubMed PMID: 28596043. DOI:10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jun 05 PubMed PMID: 28596043. DOI:10.1016/S0140-6736(17)31279-5.
   Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017 Apr 20;376(16):1551–1560. PubMed PMID: 28423301. DOI:10.1056/NEJMoa1607017
   PubMed Web of Science ®Google Scholar
• New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira in Treatment of Moderate to Severe Plaque Psoriasis [internet]. 2017 cited 2017 Jun 20. Available from: https://www.jnj.com/media-center/press-releases/new-results-from-second-phase-3-study-show-significant-efficacy-of-guselkumab-and-superiority-versus-humira-in-treatment-of-moderate-to-severe-plaque-psoriasis.
   Google Scholar
• [cited 2017 Sep 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf.RipiHoPIrAf.
   Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan;56(1):31 e1–15. PubMed PMID: 17097378. DOI:10.1016/j.jaad.2006.07.017
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) [package insert] Highlights of prescribing Information. [cited 2017 Sep 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf.
   Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs. 2008;22(5): 331–337. PubMed PMID: 18778114.
   PubMed Web of Science ®Google Scholar
• Kaplan G, Freedman VH. The role of cytokines in the immune response to tuberculosis. Res Immunol. 1996 Oct-Dec;147(8–9):565–572. PubMed PMID: 9127889.
   PubMedGoogle Scholar
• Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol. 1991 Apr;49(4):380–387. PubMed PMID: 1900522.
   PubMed Web of Science ®Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003 Nov;48(11):3013–3022. PubMed PMID: 14613261. DOI:10.1002/art.11301.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104. PubMed PMID: 11596589. DOI:10.1056/NEJMoa011110
   PubMed Web of Science ®Google Scholar
• Solomon DH. The comparative safety and effectiveness of TNF-alpha antagonists [corrected]. J Manag Care Pharm. 2007 Jan;13(1 Suppl):S7–18. PubMed PMID: 17378700.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004 Oct 15;39(8):1254–1255. PubMed PMID: 15486857. DOI:10.1086/424455
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}. Ann Rheum Dis. 2005 Nov;64(Suppl 4):iv29–30. PubMed PMID: 16239382; PubMed Central PMCID: PMCPMC1766906. DOI:10.1136/ard.2005.042390.
   PubMedGoogle Scholar
• Kaminska E, Patel I, Dabade TS, et al. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. J Dermatolog Treat. 2013 Apr;24(2):101–106. PubMed PMID: 21756157. DOI:10.3109/09546634.2011.595574
   PubMed Web of Science ®Google Scholar
• Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008 Aug;59(2):209–217. PubMed PMID: 18485527. DOI:10.1016/j.jaad.2008.03.023
   PubMed Web of Science ®Google Scholar
• Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017 Nov;17(11):1363–1374. PubMed PMID: 28791896. DOI:10.1080/14712598.2017.1363884
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Bissonnette R, Teixeira HD, et al. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol. 2016 Sep;75(3):612–618 e6. PubMed PMID: 27061047. DOI:10.1016/j.jaad.2016.02.1221
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016 Jul 28;375(4):345–356. PubMed PMID: 27299809. DOI:10.1056/NEJMoa1512711
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2016 Jun;6(2):111–124. PubMed PMID: 27221323; PubMed Central PMCID: PMCPMC4906115. DOI:10.1007/s13555-016-0121-x
   PubMed Web of Science ®Google Scholar
• [cited 2017 Sep 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf. SsPiHoPIRAa.
   Google Scholar
• Griffiths CEM, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. New England J Med. 2010;362(2):118–128. PubMed PMID: 20071701. DOI:10.1056/NEJMoa0810652
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet. 2008;371(9625):1665–1674. DOI:10.1016/S0140-6736(08)60725-4.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet. 2008;371(9625):1675–1684. DOI:10.1016/S0140-6736(08)60726-6.
   PubMed Web of Science ®Google Scholar
• Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011 Dec;22(6):337–347. PubMed PMID: 21034290. DOI:10.3109/09546634.2010.499931
   PubMed Web of Science ®Google Scholar
• Guenther L, Han C, Szapary P, et al. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):851–857. PubMed PMID: 21521375. DOI:10.1111/j.1468-3083.2011.04082.x
   PubMed Web of Science ®Google Scholar
• Papp KA, Strober B, Augustin M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012 Oct;11(10):1210–1217. PubMed PMID: 23134986.
   PubMed Web of Science ®Google Scholar
• Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016 May;74(5):851–61 e4. PubMed PMID: 26853180. DOI:10.1016/j.jaad.2015.12.017
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Jama. 2011 Aug 24;306(8):864–871. PubMed PMID: 21862748. DOI:10.1001/jama.2011.1211
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706–714. PubMed PMID: 26151787.
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011 Apr;164(4):862–872. PubMed PMID: 21332467. DOI:10.1111/j.1365-2133.2011.10257.x
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016 Jul;41(5):564–566. PubMed PMID: 27028505. DOI:10.1111/ced.12850
   PubMed Web of Science ®Google Scholar
• Napolitano M, Balato N, Ayala F, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital Dermatol Venereol. 2016 Dec;151(6):587–595. PubMed PMID: 26199090.
   PubMed Web of Science ®Google Scholar
• Siliq [package insert]. Laval (CAN): Valeant Pharmaceuticals. 2017. [cited 2017 Sep 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
   Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016 Jan;74(1):190–192. PubMed PMID: 26702804. DOI:10.1016/j.jaad.2015.08.057.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar;170(3):705–715. PubMed PMID: 24079852; PubMed Central PMCID: PMCPMC4153951. DOI:10.1111/bjd.12636
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015 Jun;26(3):235–239. PubMed PMID: 25078334. DOI:10.3109/09546634.2014.943687
   PubMed Web of Science ®Google Scholar
• Taltz (Ixekizumab) [prescribing information]. Indianapolis (IN): Eli Lilly & Co; 2017. [cited 2017 Sep 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf.
   Google Scholar
• Guenther L, Warren RB, Cather JC, et al. Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12 week results from two Phase 3 trials. J Eur Acad Dermatol Venereol. 2017 Jun 02 PubMed PMID: 28573743. DOI:10.1111/jdv.14377.
   Web of Science ®Google Scholar
• Kimball AB, Luger T, Gottlieb A, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016 Dec;75(6):1156–1161. PubMed PMID: 27692498. DOI:10.1016/j.jaad.2016.07.034
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016 Jun 01;152(6):661–669. PubMed PMID: 26953848. DOI:10.1001/jamadermatol.2016.0269
   PubMed Web of Science ®Google Scholar
• Cosentyx (secukinumab) [prescribing information]. Switzerland: Novartis Pharmaceutical Corporation; 2016. [cited 2017 Sep 2]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf.
   Google Scholar
• Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015 Sep;173(3):777–787. PubMed PMID: 25823958. DOI:10.1111/bjd.13814
   PubMed Web of Science ®Google Scholar
• Korman NJ, Sofen H, Fretzin S, et al. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Treat. 2016 Nov 21:1–6. PubMed PMID: 27832717. DOI: 10.1080/09546634.2016.1255306
   Web of Science ®Google Scholar
• Strober B, Gottlieb AB, Sherif B, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655–661. PubMed PMID: 28087133. DOI:10.1016/j.jaad.2016.11.043
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017 Jul;177(1):47–62. PubMed PMID: 27580411. DOI:10.1111/bjd.15015
   PubMed Web of Science ®Google Scholar
• Plantinga TS, Johnson MD, Scott WK, et al. Human genetic susceptibility to Candida infections. Med Mycol. 2012 Nov;50(8):785–794. PubMed PMID: 22662758. DOI:10.3109/13693786.2012.690902
   PubMed Web of Science ®Google Scholar
• Wang M, Xu G, Lu L, et al. Genetic polymorphisms of IL-17A, IL-17F, TLR4 and miR-146a in association with the risk of pulmonary tuberculosis. Sci Rep. 2016 Jun 24;6:28586. PubMed PMID: 27339100; PubMed Central PMCID: PMCPMC4919632. DOI:10.1038/srep28586
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003 Jan;52(1):65–70. PubMed PMID: 12477762; PubMed Central PMCID: PMCPMC1773503.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004 Jan;110(1):55–62. PubMed PMID: 14962796. DOI:10.1016/j.clim.2003.09.013
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016 Nov;111(11):1599–1607. PubMed PMID: 27481309. DOI:10.1038/ajg.2016.298
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700. PubMed PMID: 22595313; PubMed Central PMCID: PMCPMC4902107. DOI:10.1136/gutjnl-2011-301668
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116–124 e7. PubMed PMID: 25769911. DOI:10.1016/j.jaci.2015.01.018
   PubMed Web of Science ®Google Scholar
• [cited 2017 Aug 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf. TgPiHoPIRAa.
   Google Scholar
• Yiu ZZ, Warren RB. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. Expert Opin Investig Drugs. 2017 Feb;26(2):243–249. PubMed PMID: 28042732. DOI:10.1080/13543784.2017.1274734
   PubMed Web of Science ®Google Scholar
• Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006 Dec;18(6):347–361. PubMed PMID: 16997570. DOI:10.1016/j.smim.2006.07.010
   PubMed Web of Science ®Google Scholar
• Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012 Mar;51(3):571–576. PubMed PMID: 22157469. DOI:10.1093/rheumatology/ker365
   PubMed Web of Science ®Google Scholar
• Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006 Apr;54(4):685–704. PubMed PMID: 16546593. DOI:10.1016/j.jaad.2005.10.008.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Fleischer AB Jr., Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997 Oct;37(4):564–569. PubMed PMID: 9344194.
   PubMed Web of Science ®Google Scholar
• De Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004 Mar;9(2):140–147. PubMed PMID: 15083781. DOI:10.1046/j.1087-0024.2003.09110.x
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001 Apr;45(2):151–158. PubMed PMID: 11324779. DOI:10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T
   PubMedGoogle Scholar
• Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4(12): 833–842. PubMed PMID: 14640776.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009 May;68(5):702–709. PubMed PMID: 18684743; PubMed Central PMCID: PMCPMC2663711. DOI:10.1136/ard.2008.092767
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, De Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug;64(8):1150–1157. PubMed PMID: 15677701; PubMed Central PMCID: PMCPMC1755609. DOI:10.1136/ard.2004.032268
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr;52(4):1227–1236. PubMed PMID: 15818699. DOI:10.1002/art.20967
   PubMed Web of Science ®Google Scholar
• Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1374–1382. PubMed PMID: 19563497. DOI:10.1111/j.1468-3083.2009.03321.x
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–2272. PubMed PMID: 15248226. DOI:10.1002/art.20335
   PubMed Web of Science ®Google Scholar
• Prinz JC, Fitzgerald O, Boggs RI, et al. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol. 2011 May;25(5):559–564. PubMed PMID: 20840349. DOI:10.1111/j.1468-3083.2010.03838.x
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008 Nov;159(5):1177–1185. PubMed PMID: 18673365. DOI:10.1111/j.1365-2133.2008.08771.x
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014 Jan;73(1):48–55. PubMed PMID: 23942868; PubMed Central PMCID: PMCPMC3888622. DOI:10.1136/annrheumdis-2013-203696
   PubMed Web of Science ®Google Scholar
• Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1085–1092. PubMed PMID: 24339179; PubMed Central PMCID: PMCPMC4171746. DOI:10.1002/acr.22256
   PubMed Web of Science ®Google Scholar
• Mease PJ, Van Der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79–87. PubMed PMID: 27553214; PubMed Central PMCID: PMCPMC5264219. DOI:10.1136/annrheumdis-2016-209709
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137–1146. PubMed PMID: 26135703. DOI:10.1016/S0140-6736(15)61134-5
   PubMed Web of Science ®Google Scholar
• Strand V, Mease P, Gossec L, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017 Jan;76(1):203–207. PubMed PMID: 27169431. DOI:10.1136/annrheumdis-2015-209055
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Mutebi A, et al. Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol. 2016 Feb;43(2):343–349. PubMed PMID: 26773108. DOI:10.3899/jrheum.150182
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014 Jun 12;370(24):2295–2306. PubMed PMID: 24918373. DOI:10.1056/NEJMoa1315231
   PubMed Web of Science ®Google Scholar
• Deodhar AAGA, Boehncke WH, Dong B, et al. Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. 2016;68(supple):10.
   Google Scholar
• Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012 Jul;71(7):1143–1150. PubMed PMID: 22258482; PubMed Central PMCID: PMCPMC3375587. DOI:10.1136/annrheumdis-2011-200387
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012 Apr;148(4):487–494. PubMed PMID: 22508874; PubMed Central PMCID: PMCPMC3476943. DOI:10.1001/archdermatol.2012.370
   PubMedGoogle Scholar
• Jungo P, Maul JT, Djamei V, et al. Superiority in quality of life improvement of biologics over conventional systemic drugs in a Swiss Real-Life Psoriasis Registry. Dermatology. 2016;232(6):655–663. PubMed PMID: 28103601. DOI:10.1159/000455042
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37–49. PubMed PMID: 26089047. DOI:10.1016/j.jaad.2015.03.049
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec;173(6):1387–1399. PubMed PMID: 26357944. DOI:10.1111/bjd.14164
   PubMed Web of Science ®Google Scholar
• Loos A, Liu S, Segel C, et al. Comparative effectiveness of targeted immunomodulatorsfor the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis [Poster]. Institute For Clinical And Economic Review. 2016. [cited 2017 Aug 31]. Available from: https://www.ispor.org/research_pdfs/55/pdffiles/PSY13.pdf
   Google Scholar
• Institute for Clinical and Economic Review (ICER): Comparative Effectiveness Public Advisory Council. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Final evidence report. (accessed 2017 Aug 31). 2016. Available from: https://icer-review.org/wp-content/uploads/2016/11/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf
   Google Scholar